Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma

Authors

Jonathan Corren, University of California, Los Angeles
Mario Castro, Washington University School of Medicine in St. Louis
Pascal Chanez, Aix-Marseille Université
Leonardo Fabbri, University of Modena and Reggio Emilia
Vijay N Joish, Regeneron Pharmaceuticals, Inc
Nikhil Amin, Regeneron Pharmaceuticals, Inc
Neil M H Graham, Regeneron Pharmaceuticals, Inc
Vera Mastey, Regeneron Pharmaceuticals, Inc
Adeline Abbé, Sanofi, Chilly-Mazarin
Christine Taniou, Altran Technologies
Puneet Mahajan, Sanofi, Bridgewater
Ariel Teper, Sanofi, Bridgewater
Gianluca Pirozzi, Sanofi, Bridgewater
Laurent Eckert, Sanofi, Chilly-Mazarin

Journal

Annals of allergy, asthma & immunology

Publication Date

1-1-2019

Volume

122

Issue

1

First Page

41

Last Page

49

Document Type

Open Access Publication

DOI

10.1016/j.anai.2018.08.005

Rights and Permissions

Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbé A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2. doi: 10.1016/j.anai.2018.08.005. © 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Recommended Citation

Corren, Jonathan; Castro, Mario; Chanez, Pascal; Fabbri, Leonardo; Joish, Vijay N; Amin, Nikhil; Graham, Neil M H; Mastey, Vera; Abbé, Adeline; Taniou, Christine; Mahajan, Puneet; Teper, Ariel; Pirozzi, Gianluca; and Eckert, Laurent, "Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma." Annals of allergy, asthma & immunology. 122, 1. 41 - 49. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/9048